Therapeutic potential of Thai herbal formula for cognitive impairment: A metabolomics approach for Comprehensive Insights

• Published in: Heliyon 2024-04, Vol.10 (7), p.e28027-e28027, Article e28027
• Main Authors: Akarasereenont, Pravit, Pattanapholkornsakul, Saracha, Limsuvan, Suveerawan, Mamaethong, Dollaporn, Booranasubkajorn, Suksalin, Pakaprot, Narawut, Tripatara, Pinpat, Pilakasiri, Kajee
• Format: Article
• Language: English
• Subjects: Cerebral ischemia; Cognitive impairment; Metabolomics; Thai herbal formula; YAHOM20; YHF20
• ISSN: 2405-8440; 2405-8440
• DOI: 10.1016/j.heliyon.2024.e28027

Chronic cerebral ischemia hypoperfusion plays a role in the initiation and progression of vascular dementia, which causes changes in metabolites. Currently, there is no standard treatment to treat, prevent and reduce the severity of this condition. Thai herbal Yahom no.20 (YHF20) is indicated for fatigue and dizziness. The components of YHF20 have been found to have pharmacological effects related to the pathology of chronic cerebral ischemia hypoperfusion. This study aimed to investigate metabolomic changes after YHF20 administration in a rat model of permanent bilateral common carotid artery occlusion (2-VO) induced chronic cerebral ischemia hypoperfusion, and to explore its impact on spatial learning and memory. Albino Wistar rats were randomly allocated to 5 groups; sham, 2-VO, 2-VO+ 100 mg/kg YHF20, 2-VO+300 mg/kg YHF20, and 2-VO+1000 mg/kg YHF20. The rats were administered YHF20 daily by oral gavage for 56 days after 2-VO induction. Plasma was collected weekly for metabolome change analysis using LC-MS/QTof and toxicity study. The rats were evaluated for spatial learning and memory using the Morris water maze. The results showed that 78 known metabolites and 10 tentative pathways altered after chronic cerebral hypoperfusion, although it was not able to determine the effect on memory and learning behaviors of rats. Glutathione and glutathione metabolism might be metabolite-pathway that were the affect after YHF20 administration in cerebral ischemic condition. The 4 known metabolites may be the metabolites from the constituents of YHF20 could be considered and confirmed for quality control purpose. In conclusion, YHF20 administration might contribute to metabolic changes related to cerebral ischemia condition without the effect on spatial learning and memory, including hepatotoxicity and nephrotoxicity after 56 days of treatment. Alterations in the potential metabolites may provide data support for elucidating dementia pathogenesis and selecting pathways for intervention.